Pharmaceutical

Sensei Biotherapeutics Inc. (NASDAQ:SNSE) late Thursday released initial results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug (formerly SNS-101) for cancer. The Phase 1 dose expansion trial is evaluating solnerstotug as monotherapy and in combination with Regeneron...

Johnson & Johnson (NYSE:JNJ) just hit a Golden Cross, a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day simple moving average, often seen as a sign of strengthening momentum. While the charts suggest...

Regenxbio Inc (NASDAQ:RGNX) revealed on Wednesday new interim data from two additional patients in the Phase 1/2 portion of the AFFINITY DUCHENNE trial of RGX-202, an investigational gene therapy for Duchenne muscular dystrophy. Results were presented at the 2025 Muscular Dystrophy Association (MDA...

The U.S. Food and Drug Administration granted on Tuesday Fast Track designation to Johnson & Johnson’s (NYSE:JNJ) investigational nipocalimab for moderate-to-severe Sjögren’s disease (SjD). Last year, FDA granted Breakthrough Therapy designation (BTD) for the investigational therapy...

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Sanofi SA’s (NASDAQ:SNY) Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD). In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with...

On Monday, the U.S. Food and Drug Administration issued a complete response letter (CRL) to Johnson & Johnson’s (NYSE:JNJ) Biologics License Application for a fixed combination of amivantamab and recombinant human hyaluronidase for subcutaneous administration (SC amivantamab) in patients...

Syros Pharmaceuticals Inc (NASDAQ:SYRS) revealed on Tuesday that the SELECT-MDS-1 Phase 3 trial of tamibarotene did not meet its primary endpoint of complete response rate. The trial assessed tamibarotene in combination with azacitidine in newly diagnosed higher-risk myelodysplastic syndrome (HR-...

SciSparc Ltd.(NASDAQ:SPRC), a clinical-stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND), which enables the company to proceed to Phase IIb clinical trial for its medication to treat Tourette Syndrome (TS). This...

When stocks rally, they tend to run into resistance if they reach a price level that had been resistance before. And sometimes, after hitting it they reverse and head lower. As you can see on the chart, this is what just happened with shares of Eli Lilly and Co (NYSE:LLY). This is why our team of...

Eli Lilly and Company (NYSE:LLY) stock is trading lower on Friday. The company is anticipated to release earnings on Aug. 8 for the 2024 fiscal year second quarter. Also, Eli Lilly announced promising results from its SUMMIT phase 3 clinical trial earlier this week. The Details: Analyst estimates...

Moderna, Inc. (NASDAQ:MRNA) shares are getting hit because of a bad earnings report. The Street didn't like the numbers. The shares have broken a support level and may form a new downtrend. This is why Moderna is our Stock of the Day. If a stock is trending lower, there is more supply than demand....

Evoke Pharma Inc (NASDAQ:EVOK) shares ended Tuesday down 16.40% to 42 cents after the company announced a 1-for-12 reverse stock split of its common stock, set to take effect at 12:01 a.m. ET on August 1, 2024. After-hours trading has it up 12.44% at 47 cents. The reverse stock split means that...

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) announced on Thursday topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17. The trial met its primary endpoint with Ajovy...

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares traded higher Monday after the company provided updated guidance and partnership updates at its Investor Day. The stock is continuing to move higher after hours amid a CNBC appearance from CEO Christopher Gibson. What Happened: Recursion provided...

Eli Lilly And Co (NYSE:LLY) might see a significant boost due to supply issues at competitor Novo Nordisk A/S (NYSE:NVO), according to Reddit user serkankster. $LLY up potential byu/serkankster instocks It was noted that Eli Lilly’s weight loss drug Zepbound resolved previous supply...